CD8A and melanoma: More recently, it has also been shown that in transplanted mouse models of melanoma and prostate cancer, CD8+ T cells primed in the tdLN acquired expression of the activation marker PD-1 while maintaining expression of the transcription factor Tcf7 and remaining negative for effector cytokines [27].